Which has preferable earnings and valuation, IVVD or GERN?

Invivyd has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invivyd $53.43M 3.56 -$52.49M -$0.33 N/A Geron $183.88M 4.19 -$83.50M -$0.11 N/A

Is IVVD or GERN more profitable?

Geron has a net margin of -34.17% compared to Invivyd's net margin of -183.90%. Geron's return on equity of -24.48% beat Invivyd's return on equity. Company Net Margins Return on Equity Return on Assets Invivyd -183.90% -59.73% -48.97% Geron -34.17% -24.48% -10.30%

Does the media favor IVVD or GERN?

In the previous week, Invivyd and Invivyd both had 3 articles in the media. Geron's average media sentiment score of 1.01 beat Invivyd's score of 0.82 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IVVD or SANA?

In the previous week, Sana Biotechnology had 3 more articles in the media than Invivyd. MarketBeat recorded 6 mentions for Sana Biotechnology and 3 mentions for Invivyd. Invivyd's average media sentiment score of 0.82 beat Sana Biotechnology's score of 0.54 indicating that Invivyd is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sana Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ANNX or IVVD?

Invivyd has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annexon N/A N/A -$206.69M -$1.16 N/A Invivyd $53.43M 3.56 -$52.49M -$0.33 N/A

Is ANNX or IVVD more profitable?

Annexon has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Invivyd's return on equity of -59.73% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% Invivyd -183.90% -59.73% -48.97%

Does the media favor ANNX or IVVD?

In the previous week, Invivyd had 1 more articles in the media than Annexon. MarketBeat recorded 3 mentions for Invivyd and 2 mentions for Annexon. Annexon's average media sentiment score of 1.45 beat Invivyd's score of 0.82 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Invivyd 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Invivyd (IVVD) Competitors

$0.65 -0.03 (-4.05%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$0.65 +0.00 (+0.31%)

As of 05:52 AM Eastern

Compare

IVVD vs. GERN, SANA, CADL, ANNX, and LXRX

Should you buy Invivyd stock or one of its competitors? Invivyd's main competitors and comparable companies include Geron (GERN), Sana Biotechnology (SANA), Candel Therapeutics (CADL), Annexon (ANNX), and Lexicon Pharmaceuticals (LXRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Invivyd compare to Geron?

Invivyd (NASDAQ:IVVD) and Geron (NASDAQ:GERN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Invivyd has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	3.56	-$52.49M	-$0.33	N/A
Geron	$183.88M	4.19	-$83.50M	-$0.11	N/A

Geron has a net margin of -34.17% compared to Invivyd's net margin of -183.90%. Geron's return on equity of -24.48% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
Geron	-34.17%	-24.48%	-10.30%

Invivyd has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Geron has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

In the previous week, Invivyd and Invivyd both had 3 articles in the media. Geron's average media sentiment score of 1.01 beat Invivyd's score of 0.82 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Invivyd presently has a consensus price target of $10.00, indicating a potential upside of 1,447.99%. Geron has a consensus price target of $4.00, indicating a potential upside of 233.33%. Given Invivyd's stronger consensus rating and higher possible upside, analysts clearly believe Invivyd is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

70.4% of Invivyd shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 12.3% of Invivyd shares are owned by insiders. Comparatively, 1.7% of Geron shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Geron beats Invivyd on 8 of the 14 factors compared between the two stocks.

How does Invivyd compare to Sana Biotechnology?

Invivyd (NASDAQ:IVVD) and Sana Biotechnology (NASDAQ:SANA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Invivyd has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	3.56	-$52.49M	-$0.33	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

Sana Biotechnology has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Invivyd's return on equity of -59.73% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
Sana Biotechnology	N/A	-103.02%	-39.16%

In the previous week, Sana Biotechnology had 3 more articles in the media than Invivyd. MarketBeat recorded 6 mentions for Sana Biotechnology and 3 mentions for Invivyd. Invivyd's average media sentiment score of 0.82 beat Sana Biotechnology's score of 0.54 indicating that Invivyd is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Invivyd presently has a consensus target price of $10.00, suggesting a potential upside of 1,447.99%. Sana Biotechnology has a consensus target price of $9.33, suggesting a potential upside of 287.28%. Given Invivyd's higher possible upside, analysts clearly believe Invivyd is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

70.4% of Invivyd shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 12.3% of Invivyd shares are owned by insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Invivyd has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market.

Summary

Sana Biotechnology beats Invivyd on 9 of the 15 factors compared between the two stocks.

How does Invivyd compare to Candel Therapeutics?

Invivyd (NASDAQ:IVVD) and Candel Therapeutics (NASDAQ:CADL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

In the previous week, Invivyd had 2 more articles in the media than Candel Therapeutics. MarketBeat recorded 3 mentions for Invivyd and 1 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 1.79 beat Invivyd's score of 0.82 indicating that Candel Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Invivyd	Positive
Candel Therapeutics	Very Positive

Candel Therapeutics has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Invivyd's return on equity of -59.73% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
Candel Therapeutics	N/A	-76.98%	-48.50%

70.4% of Invivyd shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 12.3% of Invivyd shares are owned by insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Invivyd has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.32, suggesting that its share price is 132% less volatile than the broader market.

Invivyd presently has a consensus price target of $10.00, indicating a potential upside of 1,447.99%. Candel Therapeutics has a consensus price target of $20.14, indicating a potential upside of 117.29%. Given Invivyd's higher possible upside, analysts plainly believe Invivyd is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Candel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Candel Therapeutics has lower revenue, but higher earnings than Invivyd. Candel Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	3.56	-$52.49M	-$0.33	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A

Summary

Invivyd and Candel Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Invivyd compare to Annexon?

Annexon (NASDAQ:ANNX) and Invivyd (NASDAQ:IVVD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Invivyd has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Invivyd	$53.43M	3.56	-$52.49M	-$0.33	N/A

70.4% of Invivyd shares are owned by institutional investors. 10.3% of Annexon shares are owned by insiders. Comparatively, 12.3% of Invivyd shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Annexon presently has a consensus price target of $15.29, indicating a potential upside of 299.10%. Invivyd has a consensus price target of $10.00, indicating a potential upside of 1,447.99%. Given Invivyd's higher probable upside, analysts plainly believe Invivyd is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Invivyd had 1 more articles in the media than Annexon. MarketBeat recorded 3 mentions for Invivyd and 2 mentions for Annexon. Annexon's average media sentiment score of 1.45 beat Invivyd's score of 0.82 indicating that Annexon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Invivyd	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annexon has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Invivyd's return on equity of -59.73% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Invivyd	-183.90%	-59.73%	-48.97%

Annexon has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, Invivyd has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Summary

Invivyd beats Annexon on 9 of the 14 factors compared between the two stocks.

How does Invivyd compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Invivyd (NASDAQ:IVVD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Lexicon Pharmaceuticals presently has a consensus price target of $5.70, indicating a potential upside of 254.04%. Invivyd has a consensus price target of $10.00, indicating a potential upside of 1,447.99%. Given Invivyd's higher possible upside, analysts plainly believe Invivyd is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Lexicon Pharmaceuticals has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Invivyd has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Lexicon Pharmaceuticals has higher earnings, but lower revenue than Invivyd. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	14.39	-$50.34M	-$0.15	N/A
Invivyd	$53.43M	3.56	-$52.49M	-$0.33	N/A

In the previous week, Invivyd had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 3 mentions for Invivyd and 1 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.91 beat Invivyd's score of 0.82 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Lexicon Pharmaceuticals	Positive
Invivyd	Positive

Lexicon Pharmaceuticals has a net margin of -147.38% compared to Invivyd's net margin of -183.90%. Lexicon Pharmaceuticals' return on equity of -37.53% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%
Invivyd	-183.90%	-59.73%	-48.97%

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Comparatively, 12.3% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Lexicon Pharmaceuticals beats Invivyd on 11 of the 14 factors compared between the two stocks.

Get Invivyd News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IVVD vs. The Competition

Export

Metric	Invivyd	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$198.46M	$3.93B	$7.26B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	N/A	10.58	200.71	19.51
Price / Sales	3.56	1,143.64	560.30	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	0.62	16.93	10.70	6.03
Net Income	-$52.49M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-11.34%	-4.40%	-2.89%	-2.34%
1 Month Performance	-27.42%	-12.46%	-7.37%	-5.31%
1 Year Performance	-60.37%	7.64%	2.97%	-2.94%

Invivyd Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IVVD Invivyd	3.6312 of 5 stars	$0.65 -4.1%	$10.00 +1,448.0%	-65.6%	$198.46M	$53.43M	N/A	122
GERN Geron	2.4624 of 5 stars	$1.21 -1.2%	$4.00 +232.0%	-5.5%	$774.18M	$204.56M	N/A	258	Positive News
SANA Sana Biotechnology	3.4242 of 5 stars	$2.56 -2.4%	$9.33 +264.9%	-44.5%	$767.86M	N/A	N/A	142	News Coverage
CADL Candel Therapeutics	2.8822 of 5 stars	$9.66 -1.2%	$20.14 +108.6%	+43.3%	$746.44M	N/A	N/A	55
ANNX Annexon	3.8012 of 5 stars	$3.86 -2.6%	$15.29 +296.4%	+27.2%	$732.73M	N/A	N/A	92	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IVVD) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Invivyd (IVVD) Competitors

IVVD vs. GERN, SANA, CADL, ANNX, and LXRX

How does Invivyd compare to Geron?

Summary

How does Invivyd compare to Sana Biotechnology?

Summary

How does Invivyd compare to Candel Therapeutics?

Summary

How does Invivyd compare to Annexon?

Summary

How does Invivyd compare to Lexicon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD vs. The Competition

Invivyd Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Invivyd (IVVD) Competitors

IVVD vs. GERN, SANA, CADL, ANNX, and LXRX

How does Invivyd compare to Geron?

Which has preferable earnings and valuation, IVVD or GERN?

Is IVVD or GERN more profitable?

Which has more risk & volatility, IVVD or GERN?

Does the media favor IVVD or GERN?

Do analysts rate IVVD or GERN?

Do insiders & institutionals have more ownership in IVVD or GERN?

Summary

How does Invivyd compare to Sana Biotechnology?

Which has stronger valuation and earnings, IVVD or SANA?

Is IVVD or SANA more profitable?

Does the media favor IVVD or SANA?

Do analysts prefer IVVD or SANA?

Do insiders and institutionals hold more shares of IVVD or SANA?

Which has more risk & volatility, IVVD or SANA?

Summary

How does Invivyd compare to Candel Therapeutics?

Does the media prefer IVVD or CADL?

Is IVVD or CADL more profitable?

Do institutionals & insiders believe in IVVD or CADL?

Which has more risk & volatility, IVVD or CADL?

Do analysts prefer IVVD or CADL?

Which has better earnings & valuation, IVVD or CADL?

Summary

How does Invivyd compare to Annexon?

Which has preferable valuation & earnings, ANNX or IVVD?

Do insiders and institutionals believe in ANNX or IVVD?

Do analysts rate ANNX or IVVD?

Does the media favor ANNX or IVVD?

Is ANNX or IVVD more profitable?

Which has more risk and volatility, ANNX or IVVD?

Summary

How does Invivyd compare to Lexicon Pharmaceuticals?

Do analysts recommend LXRX or IVVD?

Which has more volatility & risk, LXRX or IVVD?

Which has better earnings & valuation, LXRX or IVVD?

Does the media refer more to LXRX or IVVD?

Is LXRX or IVVD more profitable?

Do institutionals and insiders believe in LXRX or IVVD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD vs. The Competition

Invivyd Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools